Please use this identifier to cite or link to this item:
Type
ArticleCopyright
Restricted access
Sustainable Development Goals
03 Saúde e Bem-EstarCollections
Metadata
Show full item record
CCL3, CCL5, IL-15, IL-1RA AND VEGF COMPOSE A RELIABLE ALGORITHM TO DISCRIMINATE CLASSES OF ADVERSE EVENTS FOLLOWING 17DD-YF PRIMARY VACCINATION ACCORDING TO CAUSE-SPECIFIC DEFINITIONS
Author
Affilliation
Abstract
In the present study, a range of serum biomarkers were quantified in suspected cases of adverse events following YF immunization (YEL-AEFI) to propose a reliable laboratorial algorithm to discriminate confirmed YEL-AEFI (A1 class) from cases with other illnesses (C class). Our findings demonstrated that increased levels of CXCL8, CCL2, CXCL10, IL-1b, IL-6 and TNF-a were observed in YEL-AEFI (A1 and C classes) as compared to primary vaccines without YEL-AEFI [PV(day 3-28)] and reference range (RR) controls. Notably, increased levels of CCL3, CCL4, CCL2, CCL5, IL-1b, IL-15, IL-1Ra and G-CSF were found in A1 as compared to C class. Venn diagrams analysis allowed the pre-selection of biomarkers for further analysis of performance indices. Data demonstrated that CCL3, CCL5, IL-15 and IL-1Ra presented high global accuracy (AUC = 1.00) to discriminate A1 from C. Decision tree was proposed with a reliable algorithm to discriminate YEL-AEFI cases according to cause-specific definitions with outstanding overall accuracy (91%). CCL3, CCL5, IL-15 and IL-1Ra appears as root attributes to identify A1 followed by VEGF as branch nodes to discriminate Wild Type YFV infection (C(WT-YFV)) from cases with other illnesses (C*). Together, these results demonstrated the applicability of serum biomarker measurements as putative parameters towards the establishment of accurate laboratorial tools for complementary differential diagnosis of YEL-AEFI cases.
Share